The dysregulated expression of CLU and its correlation with tumorigenesis, along with potential clinical implications, have been extensively documented in multiple types of cancer, including lung cancer, prostate cancer, and breast cancer [13,14,15]. Here, CLU is linked to prostate carcinoma.